Home » Stocks » ADYX

Adynxx, Inc. (ADYX)

Stock Price: $0.1000 USD 0.0000 (0.00%)
Updated Jul 30, 2021 9:30 AM EDT - Market closed
Market Cap 602,277
Revenue (ttm) 589,000
Net Income (ttm) -8.73M
Shares Out 5.81M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $0.1000
Previous Close $0.1000
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.1000
Day's Range 0.1000 - 0.1000
Day's Volume 0
52-Week Range 0.0300 - 1.1800

News

There are no news available yet.

About ADYX

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Industry
Biotechnology
Founded
2007
CEO
David Johnson
Employees
6
Stock Exchange
OTCMKTS
Ticker Symbol
ADYX
Full Company Profile

Financial Performance

In 2018, Adynxx's revenue was $2.22 million, an increase of 9.76% compared to the previous year's $2.02 million. Losses were -$8.42 million, -67.26% less than in 2017.

Financial Statements